← Eichor
Study identifier: NCT07687706 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)

Condition: Ischemic Stroke · Ischemic Stroke, Acute · Transient Ischemic Attack (TIA)  ·  Sponsor: Hanyang University Guri Hospital

PhasePhase 3
Planned participants1524
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, no comparable guidance or evidence exists for stroke care. Tegoprazan is a potassium-competitive acid blocker offering rapid, meal-independent acid suppression with fewer drug interactions than proton pump inhibitors, yet whether it prevents such complications after stroke remains unknown. Thus, the investigators aim to evaluate whether tegoprazan reduces gastrointestinal complications in patients receiving antiplatelet therapy after ischemic stroke. TegoStroke is a phase 3, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at more than 20 centers in the Republic of Korea. Adult patients who are starting antiplatelet therapy after acute ischemic stroke or transient ischemic attack, and who are expected to continue it for at least 6 months, will be included. Eligible patients will be 1:1 randomized to receive oral tegoprazan 50 mg once daily or matching placebo for 180 days. The primary outcome is a composite of upper or indeterminate-origin gastrointestinal bleeding, gastric or duodenal ulcer ≥3 mm, or erosive esophagitis, ascertained up to a day-180 esophagogastroduodenoscopy. This study would provide the first randomized evidence on routine gastroprotection for p…

This description comes directly from the study's public registry record.

Talk to the study team

Seong-Ho Koh, MD, PhD  ·  +82-31-560-2267  ·  ksh213@hanyang.ac.kr

Jiyeon Ha, MD  ·  hjy9307@gmail.com

Always discuss trial participation with your own doctor first.

Locations (24)

Pusan National University HospitalBusan, Busan, South KoreaRecruiting
Keimyung University Dongsan HospitalDaegu, Daegu, South KoreaRecruiting
Hallym University Chuncheon Sacred Heart HospitalChuncheon, Gangwon-do, South KoreaRecruiting
Kangwon National University HospitalChuncheon, Gangwon-do, South KoreaRecruiting
Hallym University Sacred Heart HospitalAnyang-si, Gyeonggi-do, South KoreaRecruiting
Wonkwang University HospitalIksan, Jeollabuk-do, South KoreaRecruiting
Jeonbuk National University HospitalJeonju, Jeollabuk-do, South KoreaRecruiting
Chungbuk National University HospitalCheongju-si, North Chungcheong, South KoreaRecruiting
Dong-A University HospitalBusan, South KoreaRecruiting
Kyungpook National University Chilgok HospitalDaegu, South KoreaRecruiting
Yeungnam University Medical CenterDaegu, South KoreaRecruiting
Hanyang University Guri HospitalGuri-si, South KoreaRecruiting

+ 12 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07687706